WallStSmart

Hecla Mining Company (HL)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Hecla Mining Company generates 4587% more annual revenue ($1.63B vs $34.76M). VMET leads profitability with a 58.5% profit margin vs 16.8%. HL trades at a lower P/E of 30.0x. HL earns a higher WallStSmart Score of 69/100 (B-).

HL

Strong Buy

69

out of 100

Grade: B-

Growth: 10.0Profit: 8.5Value: 4.7Quality: 6.8
Piotroski: 5/9Altman Z: 2.13

VMET

Hold

45

out of 100

Grade: D+

Growth: 8.0Profit: 8.0Value: 4.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HLUndervalued (+2.5%)

Margin of Safety

+2.5%

Fair Value

$24.30

Current Price

$19.45

$4.85 discount

UndervaluedFair: $24.30Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HL3 strengths · Avg: 10.0/10
Operating MarginProfitability
55.5%10/10

Strong operational efficiency at 55.5%

Revenue GrowthGrowth
100.4%10/10

Revenue surging 100.4% year-over-year

EPS GrowthGrowth
952.0%10/10

Earnings expanding 952.0% YoY

VMET3 strengths · Avg: 10.0/10
Profit MarginProfitability
58.5%10/10

Keeps 59 of every $100 in revenue as profit

Operating MarginProfitability
135.6%10/10

Strong operational efficiency at 135.6%

Revenue GrowthGrowth
465.2%10/10

Revenue surging 465.2% year-over-year

Areas to Watch

HL2 concerns · Avg: 3.0/10
P/E RatioValuation
30.0x4/10

Moderate valuation

PEG RatioValuation
5.642/10

Expensive relative to growth rate

VMET3 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.32B3/10

Smaller company, higher risk/reward

P/E RatioValuation
58.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : HL

The strongest argument for HL centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 16.8% and operating margin at 55.5%. Revenue growth of 100.4% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.5% and operating margin at 135.6%. Revenue growth of 465.2% demonstrates continued momentum.

Bear Case : HL

The primary concerns for HL are P/E Ratio, PEG Ratio.

Bear Case : VMET

The primary concerns for VMET are EPS Growth, Market Cap, P/E Ratio. A P/E of 58.0x leaves little room for execution misses.

Key Dynamics to Monitor

VMET is growing revenue faster at 465.2% — sustainability is the question.

HL generates stronger free cash flow (155M), providing more financial flexibility.

Monitor OTHER PRECIOUS METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HL scores higher overall (69/100 vs 45/100), backed by strong 16.8% margins and 100.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hecla Mining Company

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Hecla Mining Company discovers, acquires, develops and produces precious and base metal properties in the United States and internationally. The company is headquartered in Coeur d'Alene, Idaho.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing novel therapeutics for serious and life-threatening diseases, particularly through its innovative drug development platform that leverages its proprietary metalloenzyme-based technology. The company aims to address unmet medical needs in areas such as fungal infections and oncology, positioning itself at the forefront of therapeutic innovation. Viamet's strategic partnerships and strong intellectual property portfolio underscore its commitment to advancing its pipeline while maximizing shareholder value. As it progresses through clinical development phases, VMET stands to play a significant role in transforming treatment paradigms within its targeted therapeutic areas.

Want to dig deeper into these stocks?